Healthcare & Pharmaceutical Market Research in Jordan

BioNixus is a pharmaceutical market research firm serving Amman and the wider Jordanian market, designing and executing primary studies for healthcare and pharma teams operating within Jordan Food and Drug Administration (JFDA) regulated channels. Our healthcare market research agency covers HCP insight, KOL mapping, patient journey studies, and payer access research — purpose-built for Jordan's $1.5B+ pharmaceutical and healthcare market.

Looking for all-industry market research? Best market research companies in Jordan covers FMCG, consumer, and strategic research alongside healthcare capability.

Best healthcare market research company in Jordan

BioNixus is a leading healthcare market research company in Jordan, specialising in HCP surveys, KOL mapping, and market access research compliant with Jordan Food and Drug Administration (JFDA) requirements.

HCP and Physician SurveysBilingual (English/Arabic) interviews and surveys across physicians, pharmacists, and nurses in Amman and secondary Jordanian cities.
KOL Mapping and Influence AnalysisIdentify key opinion leaders and map influence networks by therapy area across King Hussein Cancer Center (KHCC) and Jordan University Hospital (JUH).
Market Access and Pricing ResearchFormulary committee research, JFDA Health Technology Assessment (HTA) analysis, and willingness-to-pay studies across Jordan healthcare channels.

BioNixus delivers primary healthcare market research in Jordan with JFDA-aligned methodologies across public and private health systems.

What we research: therapeutic areas and segments in Jordan

Oncology & hematology

King Hussein Cancer Center (KHCC) and KOL mapping across Jordan specialist networks

Generics & biosimilars

Generic substitution attitudes, biosimilar positioning, and competitive intelligence against Hikma, APM, and Dar Al Dawa

Precision medicine

Genomics adoption, personalised therapy readiness, and biomarker testing behaviour across Jordan oncology centres

Pharmacovigilance

Post-marketing surveillance design and JFDA pharmacovigilance framework research

Diabetes & metabolic

Type 1 and Type 2 treatment algorithms, GLP-1 adoption, and payer coverage across Jordan healthcare channels

Rare disease & orphan products

Jordan patient community mapping, specialist access, and compassionate use programme research

Medical devices & diagnostics

Device adoption, procurement committee behaviour, and health technology assessment research for Jordan hospital tenders

Vaccines & infectious disease

JFDA vaccine programme awareness, uptake drivers, and hesitancy research across Jordan population segments

Generic manufacturing & specialty pharma

Competitive intelligence, pricing analysis, and hospital formulary management across Jordan’s generic pharmaceutical manufacturing sector

Research audiences: who we reach in Jordan

HCPs — physicians and specialists

Prescribing oncologists, diabetologists, cardiologists, and primary care physicians across Amman hospitals and clinics, including Jordan University Hospital (JUH) and Prince Hamza Hospital.

KOLs — key opinion leaders

Jordan academic and clinical thought leaders in target therapy areas. BioNixus maps influence networks across King Hussein Cancer Center (KHCC) and JUH clinical advisory structures.

Patients and caregivers

Patient journey studies, quality-of-life research, and support programme needs assessment — conducted with ethics-appropriate consent and multilingual materials.

Payers and hospital committee members

Formulary committee chairs, insurance medical directors, hospital procurement leads, and JFDA HTA-aligned policy advisors who shape real-world access.

Pharmacists

Community and hospital pharmacist attitudes, dispensing behaviour, generic substitution practices, and patient counselling patterns across Jordan retail and institutional pharmacy.

Healthcare research methodology

Every BioNixus Jordan healthcare study begins with a single commercial or access decision — launch sequencing, payer narrative, KOL prioritisation, or competitive positioning. Instruments, sample frames, and analysis plans are designed backward from that decision.

We combine quantitative rigor (structured HCP surveys, segmentation, adoption models) with qualitative depth (in-depth interviews, virtual advisory boards, paired physician-payer modules) so leadership sees both the metric and the reason behind it.

Fieldwork follows healthcare research standards: screened and verified respondents, documented consent, de-identified reporting, and bilingual materials reviewed for clinical accuracy before launch. Arabic and English execution is standard across all Jordan programmes.

For advisory board and real-world evidence (RWE) programmes, BioNixus designs sessions compatible with JFDA regulatory frameworks — ensuring findings can support access dossiers and reimbursement submissions.

Regulatory and market access depth: the JFDA

Jordan operates under a single national regulator — the Jordan Food and Drug Administration (JFDA) — which governs pharmaceutical registration, clinical trial authorisation, and pharmacovigilance. The JFDA's growing Health Technology Assessment (HTA) unit is increasingly influential in formulary listing and reimbursement decisions. BioNixus designs studies that reflect JFDA-specific timelines and generic substitution policy rather than treating Jordan as an extension of the GCC market.

Jordan's healthcare and pharmaceutical market exceeds $1.5 billion, and the country hosts one of the most established generic pharmaceutical manufacturing sectors in the Arab world — led by Hikma Pharmaceuticals, Arab Pharmaceutical Manufacturing (APM), and Dar Al Dawa. This manufacturing base means formulary and pricing research must account for entrenched generic competition alongside payer and insurer mandates.

Amman's health cluster — anchored by Jordan University Hospital (JUH), King Hussein Cancer Center (KHCC), and a growing network of private hospital groups — concentrates specialist prescribing. BioNixus KOL maps and HCP studies segment by hospital, specialty, and institution so you target influence where it actually sits for your therapy area.

Why pharmaceutical teams choose BioNixus in Jordan

✓Specialist in pharma and healthcare research — not a generalist panel company running healthcare as a sideline
✓Verified Jordan physician and specialist access across JUH, KHCC, and Amman private hospital networks
✓Bilingual Arabic-English fieldwork with culturally validated instruments
✓Deep JFDA regulatory context built into study design, including HTA-aligned evidence generation
✓Dual quantitative and qualitative capability in one team — no subcontracting
✓Real-world evidence and advisory board programme design compatible with Jordan access submissions
✓15+ years of healthcare research experience across 38 countries

Related Jordan healthcare research resources

Jordan pharmaceutical market research Best market research companies in Jordan Best healthcare market research companies in Jordan Healthcare & pharma market research hub All-industry market research services

FAQs

What are the best pharmaceutical market research firms in Jordan?

BioNixus is a leading pharmaceutical market research firm serving Jordan, delivering HCP, KOL, patient, and payer studies aligned with Jordan Food and Drug Administration (JFDA) requirements. We combine primary research depth with Amman-based panel access and bilingual fieldwork.

What does a healthcare market research agency in Jordan typically do?

A healthcare market research agency in Jordan designs and executes studies covering physician attitudes, payer access, patient journeys, and competitive landscape for pharmaceutical and medical device companies operating in or entering the Jordanian market.

How does healthcare market research in Jordan differ from the GCC?

Jordan operates under a single national regulator, the Jordan Food and Drug Administration (JFDA), rather than the multi-emirate or multi-authority systems found in some GCC markets. Formulary processes, hospital procurement, and generic substitution dynamics are shaped by JFDA policy and Jordan's strong domestic generic manufacturing base. BioNixus designs studies around this single-regulator structure rather than importing GCC assumptions.

What therapeutic areas do pharmaceutical market research companies in Jordan cover?

BioNixus covers oncology, diabetes, cardiology, immunology, rare diseases, biologics, biosimilars, vaccines, medical devices, and diagnostics across the Jordanian market.

Can BioNixus recruit HCPs and KOLs in Jordan?

Yes. We maintain physician and specialist access across Jordan University Hospital (JUH), King Hussein Cancer Center (KHCC), and Amman-based private hospital networks. For scarce specialties like oncology or rare disease, we extend to hospital networks and medical association directories with longer recruitment planning.

What is the typical timeline for healthcare market research in Jordan?

Focused HCP surveys complete in 3-4 weeks. Full mixed-method programs including payer depth and advisory modules typically run 5-8 weeks depending on therapy scarcity and ethics requirements.

Does healthcare market research in Jordan cover generic and biosimilar competition?

Yes. BioNixus runs studies covering generic substitution attitudes, biosimilar adoption, and competitive positioning against Jordan's established generic manufacturers — reflecting the country's role as one of the region's leading generic pharmaceutical exporters.

Where can I find general (non-healthcare) market research in Jordan?

See our Best Market Research Companies in Jordan guide for all-industry research spanning FMCG, consumer, and strategic research alongside healthcare and pharmaceutical capability.

Discuss your Jordan pharmaceutical research strategy

Our team supports pharmaceutical companies with decision-ready insights across the Americas, Europe, and the Middle East using quantitative and qualitative methodologies.

Request a proposal Email us

US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323